Khemka S, Reddy A, Garcia R, Jacobs M, Reddy R, Roghani A
Ageing Res Rev. 2023; 91:102091.
PMID: 37832608
PMC: 10842571.
DOI: 10.1016/j.arr.2023.102091.
Ahn C, Oh T, Min S, Cho Y
Endocrinol Metab (Seoul). 2023; 38(1):1-9.
PMID: 36781163
PMC: 10008660.
DOI: 10.3803/EnM.2023.103.
Shirabe S, Yamazaki K, Oishi M, Arai K, Yagi N, Sato M
J Diabetes Investig. 2022; 14(1):75-80.
PMID: 36268571
PMC: 9807151.
DOI: 10.1111/jdi.13922.
Kadowaki T, Inagaki N, Watada H, Sasaki K, Mori-Anai K, Iwasaki T
Adv Ther. 2022; 39(4):1642-1658.
PMID: 35138572
PMC: 8989929.
DOI: 10.1007/s12325-021-02038-5.
Yagi N, Komiya I, Arai K, Oishi M, Fukumoto Y, Shirabe S
J Diabetes Investig. 2021; 13(1):65-73.
PMID: 34191401
PMC: 8756302.
DOI: 10.1111/jdi.13621.
Efficacy and safety of a combination of an insulin secretagogue and a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes mellitus; the repaglinide glucose oscillation study in Fukuoka (REGO-F).
Terawaki Y, Iwaya C, Nomiyama T, Shimono D, Horikawa T, Fujimura-Tanaka Y
Diabetol Int. 2020; 11(3):274-282.
PMID: 32802709
PMC: 7387390.
DOI: 10.1007/s13340-020-00426-w.
Long-Term, Real-World Safety and Efficacy of Teneligliptin: A Post-Marketing Surveillance of More Than 10,000 Patients with Type 2 Diabetes in Japan.
Kadowaki T, Haneda M, Ito H, Sasaki K, Matsukawa M, Yamada Y
Adv Ther. 2019; 37(3):1065-1086.
PMID: 31873865
PMC: 7089720.
DOI: 10.1007/s12325-019-01189-w.
Treatment patterns of drug-naive patients with type 2 diabetes mellitus: a retrospective cohort study using a Japanese hospital database.
Morita Y, Murayama H, Odawara M, Bauer M
Diabetol Metab Syndr. 2019; 11:90.
PMID: 31695754
PMC: 6824122.
DOI: 10.1186/s13098-019-0486-y.
Fusion pore regulation by cAMP/Epac2 controls cargo release during insulin exocytosis.
Gucek A, Gandasi N, Omar-Hmeadi M, Bakke M, Doskeland S, Tengholm A
Elife. 2019; 8.
PMID: 31099751
PMC: 6557626.
DOI: 10.7554/eLife.41711.
Consensus Recommendations on Sulfonylurea and Sulfonylurea Combinations in the Management of Type 2 Diabetes Mellitus - International Task Force.
Kalra S, Bahendeka S, Sahay R, Ghosh S, Md F, Orabi A
Indian J Endocrinol Metab. 2018; 22(1):132-157.
PMID: 29535952
PMC: 5838894.
DOI: 10.4103/ijem.IJEM_556_17.
Incretin-based drugs for type 2 diabetes: Focus on East Asian perspectives.
Seino Y, Kuwata H, Yabe D
J Diabetes Investig. 2016; 7 Suppl 1:102-9.
PMID: 27186364
PMC: 4854513.
DOI: 10.1111/jdi.12490.
Assessing the efficacy and safety of combined DPP-4 inhibitor and insulin treatment in patients with type 2 diabetes: a meta-analysis.
Chen C, Yu Q, Zhang S, Yang P, Wang C
Int J Clin Exp Pathol. 2016; 8(11):14141-50.
PMID: 26823727
PMC: 4713513.
Survey of Hypoglycemia in Elderly People With Type 2 Diabetes Mellitus in Japan.
Fukuda M, Doi K, Sugawara M, Naka Y, Mochizuki K
J Clin Med Res. 2015; 7(12):967-78.
PMID: 26566411
PMC: 4625818.
DOI: 10.14740/jocmr2340w.
Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statement.
Kalra S, Aamir A, Raza A, Das A, Azad Khan A, Shrestha D
Indian J Endocrinol Metab. 2015; 19(5):577-96.
PMID: 26425465
PMC: 4566336.
DOI: 10.4103/2230-8210.163171.
Incretin physiology and pathophysiology from an Asian perspective.
Cho Y
J Diabetes Investig. 2015; 6(5):495-507.
PMID: 26417406
PMC: 4578486.
DOI: 10.1111/jdi.12305.
Two-year assessment of the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes: Post hoc analysis of the ASSET-K study.
Umezawa S, Kubota A, Maeda H, Kanamori A, Matoba K, Jin Y
BMC Endocr Disord. 2015; 15:34.
PMID: 26137940
PMC: 4490678.
DOI: 10.1186/s12902-015-0033-2.
β cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in East Asians.
Yabe D, Seino Y, Fukushima M, Seino S
Curr Diab Rep. 2015; 15(6):602.
PMID: 25944304
PMC: 4420838.
DOI: 10.1007/s11892-015-0602-9.
Albiglutide: a review of its use in patients with type 2 diabetes mellitus.
Blair H, Keating G
Drugs. 2015; 75(6):651-63.
PMID: 25777969
DOI: 10.1007/s40265-015-0370-5.
